5 Decades of Mouse Models That Shaped Every Major Diabetes Drug We Use Today
Diabetes mellitus currently affects more than 589 million adults worldwide. Patients rely on daily self-monitoring of blood glucose, exogenous insulin therapy, pharmacological interventions, and continuous vigilance to prevent or mitigate serious complications, including cardiovascular disease, chronic kidney disease, retinopathy, and neuropathy. Recent epidemiological projections indicate that the global prevalence will rise to approximately 853 million adults by 2050 [1].
At the same time, substantial progress is being made in therapeutic innovation. Stem cell-derived islet transplantation is being developed to restore endogenous insulin production in individuals with type 1 diabetes (T1D). Small interfering RNA (siRNA) therapeutics are targeting novel metabolic pathways in type 2 diabetes (T2D). Monoclonal antibodies are under investigation to protect pancreatic β-cells from autoimmune destruction. In parallel, advanced humanized mouse models are enhancing the translational relevance of preclinical research, accelerating the progression of these and other candidate therapies from bench to bedside.
For a long time, making new diabetes drugs has relied heavily on lab mice. These mice have been crucial for helping scientists understand how the disease works and test new treatments.
Today, these mouse models are being upgraded to act more like humans. By better matching human bodies and immune systems, they make early lab tests much more accurate. This helps researchers in their search for treatments that can truly change or even cure diabetes.
The Legacy of Diabetes Mouse Models: ob/ob, db/db, and NOD Mice in T1D/T2D Drug Discovery
Rodent models have revolutionized diabetes research over decades. They allowed scientists to study insulin resistance, beta-cell dysfunction, obesity, and autoimmune processes long before human trials.
Two key models are the ob/ob and db/db mice. The ob/ob mouse resulted from a spontaneous leptin gene mutation identified in the late 1940s to early 1950s. It displays constant eating, extreme obesity, severe insulin resistance, and hyperglycemia. Discovered around 1966, the db/db mouse has a leptin receptor mutation, showing similar obesity and diabetes but with high leptin levels. Its consistent hyperglycemia and complications, such as kidney damage, make db/db mice a mainstay for type 2 diabetes studies.
These monogenic models proved instrumental in drug development. They validated targets in energy balance and insulin signaling; ob/ob research in the 1990s led to leptin’s discovery. They have been used to screen insulin sensitizers, test glucose-lowering agents, study adipose inflammation, and evaluate complications. While they do not fully recapitulate polygenic human type 2 diabetes and differ in some complications and wound healing, they offer fast, reproducible platforms for early efficacy and mechanism studies that supported incretin and metabolic therapies.
For Type 1 diabetes (T1D), the Non-Obese Diabetic (NOD) mouse and streptozotocin (STZ)-induced models have been especially influential. The NOD mouse, developed in Japan in 1974, spontaneously develops autoimmune insulitis and beta-cell destruction driven by multiple genes, including MHC class II alleles [4].
This closely mirrors the immune processes seen in human T1D. STZ, a beta-cell toxin, produces insulin deficiency and has been widely used to test replacement therapies and protective strategies.
These models supported decades of research on immunomodulation, islet transplantation, and beta-cell preservation. They also contributed to the development of therapies such as teplizumab, an anti-CD3 monoclonal antibody now approved to delay T1D onset [5].
Evolution of Diabetes Mouse Models: From Spontaneous Mutants to Humanized Systems for Enhanced Translational Research
Early models relied on chemical inducers such as alloxan or STZ and spontaneous mutants. Researchers later moved toward diet-induced approaches, such as high-fat feeding, and genetically engineered systems including transgenic and knockout mice. These offered better relevance to human lifestyle factors and specific molecular pathways.
However, differences between mice and humans in metabolism, immune function, and disease progression limited how well the models predicted clinical outcomes. This led to the rise of humanized mouse models, which incorporate human genes, cells, or immune systems to improve relevance for human therapies.
Diabetes Therapeutic Breakthroughs (2025–2026): Key Advances in siRNA, Monoclonal Antibodies, and Stem Cell Regeneration
The diabetes field is shifting from symptomatic management toward disease modification and regeneration.
In T2D, incretin multi-agonists such as retatrutide continue delivering strong glycemic control and cardiorenal benefits, with oral GLP-1s and once-weekly basal insulins advancing. Novel targets include INHBE; Wave’s WVE-007 GalNAc-siRNA has shown promising Phase 1 results with improvements in body composition and cardiometabolic markers. Its Phase 2a multidose study, including patients with T2D, begins in Q2 2026 [6]. Junevity’s JUN_01 siRNA for metabolic reprogramming advances toward first-in-human trials in H2 2026, with preclinical data supporting enhanced insulin sensitivity and glucose control in T2D [7]. siRNA therapies enable potent, durable gene silencing with infrequent dosing via GalNAc delivery, extending to targets such as PTP1B and TXNIP to improve insulin signaling and protect beta cells [8].
Antibody therapies progress with teplizumab delaying T1D onset and targeted agents like tegoprubart supporting safer islet transplantation, with 2026 data showing high rates of insulin independence [9]. Emerging monoclonals explore direct beta-cell protection.
Regenerative approaches lead innovation. Vertex’s zimislecel stem cell-derived islets advance in Phase 3, with regulatory submissions targeted for 2026 [10]. Sana’s hypoimmune islets and improved encapsulation devices aim to reduce immunosuppression needs in T1D [11].
Why Humanized Mouse Models Are Now Essential for Accurate siRNA and Biologic Drug Development in Diabetes
Traditional mouse models often fall short when it comes to predicting human responses, particularly for immune therapies, gene-targeted drugs, and biologics. Small-interfering RNA (siRNA) therapeutics demand fully humanized genomic mouse models because their mechanism of action is strictly sequence-specific. Large-molecule biologics likewise suffer from reduced target-binding affinity due to interspecies sequence differences and therefore require mice engineered with humanized target genes. Humanized mouse models overcome these limitations by replacing key mouse genes with their human counterparts or by engrafting functional human immune systems and cells. This creates a far more relevant platform for preclinical testing, which is especially critical as diabetes research shifts toward highly precise, sequence-dependent modalities.
Cyagen’s Humanized Diabetes Mouse Models: Advanced Tools Enhancing Translational Accuracy in Preclinical Research
A prime example of this technological shift is the rising industry interest in novel metabolic targets like INHBE. With breakthrough candidates like Wave Life Sciences' GalNAc-siRNA (WVE-007), validating sequence-dependent mechanics in a preclinical setting requires an exact genetic match.
Cyagen directly addresses this necessity by providing a comprehensive portfolio of ready-to-use humanized and diabetes-related mouse models designed specifically for advanced metabolic research. Engineered for reliability, consistency, and high translational value, these models enable researchers to more effectively evaluate novel therapies across immunotherapy, gene editing, and RNA-targeted approaches.
The table below highlights Cyagen’s key diabetes mouse models.
| Catalog Number | Name | Diabetes Impact Pathway | Catalog Number Name Diabetes Impact Pathway Pathway Categories |
|---|---|---|---|
| C001368 | Lep-KO(ob/ob) | Leptin Deficiency Models | Foundational model |
| C001421 | huGLP-1R | Incretin and Glucagon Pathways | The incretin (GLP-1 and GIP) and glucagon pathways are central to glucose homeostasis. These humanized models enable precise evaluation of therapeutics that modulate insulin secretion and blood glucose levels in diabetes research. |
| C001858 | hGIPR | ||
| C001723 | huGCGR | ||
| C001601 | huGLP-1R/Lep-KO(ob/ob) | ||
| C001599 | hGLP-1R/hGIPR | ||
| C001939 | huGLP-1R/hGIPR/huGCGR | ||
| C001785 | huGCGR/huGLP-1R | ||
| I001187 | hDPP4 | ||
| I001188 | hDPP4(2) | ||
| I001189 | hDPP4(BALB/c) | ||
| C001622 | huKLB | FGF21 Signaling Pathway | FGF21 is a metabolic hormone that enhances insulin sensitivity and lipid metabolism. Humanized models for FGF21 and its signaling components (FGFR1c and KLB) facilitate studies on its role in treating obesity and type 2 diabetes. |
| C001684 | hFGFR1c | ||
| C001685 | huFGF21 | ||
| C001911 | huALK7(ACVR1C) | ALK7/INHBE Pathway | The ALK7 (ACVR1C) receptor and INHBE ligand, part of TGF-β signaling, regulate adiposity and energy expenditure. These models support research into novel metabolic targets for diabetes and obesity. |
| C001994 | huALK7/huINHBE | ||
| C001709 | hALK7(ACVR1C) | ||
| C001533 | huINHBE | ||
| C001600 | huINHBE/Lep-KO | ||
| C001549 | DIO-B6-M | Metabolic Disorder Models | These models capture diet-induced obesity and genetic defects leading to metabolic dysregulation, dyslipidemia, and diabetes complications. |
| C001859 | Gpr75-KO | ||
| C001392 | Ldlr-KO | ||
| C001778 | Alms1-del(c.3802-3812) | ||
| Humanized models for additional targets, including IAPP, RAMP1, RAMP2, RAMP3, SLC30A8, GRB14, NK2R, etc., are currently under development. | |||
Comprehensive In Vivo Metabolic CRO Services: End-to-End Diabetes Research Platforms for Faster Drug Translation
Cyagen also provides an advanced in vivo Metabolic Study Platform and full-spectrum CRO services dedicated to diabetes and metabolism-related diseases. We deliver end-to-end pharmacology and efficacy evaluation services through a robust platform that includes daily monitoring of body weight, food and water intake, and clinical signs; glucose tolerance and insulin sensitivity tests (OGTT, IPITT, GTT/ITT); metabolic cage phenotyping; body composition analysis by MRI; comprehensive blood biochemistry and DCA HbA1c assays; muscle function tests; and detailed histology and pathology (HE and PAS staining).
For example, here is a representative result from our end-to-end diabetes research platform demonstrating the efficacy of Tirzepatide:
Contact us for more examples of successful studies conducted by Cyagen.
Conclusion: Utilizing Advanced Mouse Models and Full-Service CRO to Accelerate Diabetes Drug Development
In conclusion, over five decades, mouse models have been instrumental in developing every major diabetes therapy in clinical use today, from insulin sensitizers to immunomodulators. As the field shifts toward disease-modifying and regenerative approaches such as siRNA, monoclonal antibodies, and stem cell-derived islets, advanced humanized mouse models have become essential for improving translational accuracy and accelerating progress. Cyagen’s specialized diabetes models and full-service CRO platform empower researchers to bridge bench discoveries to bedside cures faster than ever.
Reference
[1] Genitsaridi I, Salpea P, Salim A, Sajjadi SF, Tomic D, James S, Thirunavukkarasu S, Issaka A, Chen L, Basit A, Luk AOY, Ma RCW, Mbanya JC, Ramachandran A, Wild SH, Duncan BB, Boyko EJ, Magliano DJ. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol. 2026 Feb;14(2):149-156. doi: 10.1016/S2213-8587(25)00299-2. Epub 2025 Dec 15. PMID: 41412135.
[2] Singh A, Afshan N, Singh A, Singh SK, Yadav S, Kumar M, Sarma DK, Verma V. Recent trends and advances in type 1 diabetes therapeutics: A comprehensive review. Eur J Cell Biol. 2023 Jun;102(2):151329. doi: 10.1016/j.ejcb.2023.151329. Epub 2023 Jun 5. PMID: 37295265.
[3] Suriano F, Vieira-Silva S, Falony G, Roumain M, Paquot A, Pelicaen R, Régnier M, Delzenne NM, Raes J, Muccioli GG, Van Hul M, Cani PD. Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin. Microbiome. 2021 Jun 28;9(1):147. doi: 10.1186/s40168-021-01097-8. PMID: 34183063; PMCID: PMC8240277.
[4] Wong FS, Pearson JA, Wen L. Is the NOD mouse a good model for type 1 diabetes? Diabetologia. 2026 Jan;69(1):3-19. doi: 10.1007/s00125-025-06579-0. Epub 2025 Nov 8. PMID: 41206392; PMCID: PMC12686005.
[5] Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):123-7. doi: 10.1073/pnas.91.1.123. PMID: 8278351; PMCID: PMC42898.
[6] Wave Life Sciences Ltd. Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007 [Internet]. Cambridge (MA): Wave Life Sciences Ltd.; 2026 Mar 26 [cited 2026 May 22]. Available from: https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-interim-phase-1-data
[7] Junevity. Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA [Internet]. San Francisco: Business Wire; 2025 Dec 3 [cited 2026 May 22]. Available from: https://www.businesswire.com/news/home/20251203837496/en/Junevity-Expands-Seed-Funding-to-%2420-Million-for-Cell-Reprogramming-with-siRNA
[8] Khan MT, Al-Dhaleai RE, Alayadhi SM, Alhalwachi Z, Butler AE. The Role of Gene Therapy and RNA-Based Therapeutic Strategies in Diabetes. Int J Mol Sci. 2025 Oct 22;26(21):10264. doi: 10.3390/ijms262110264. PMID: 41226304; PMCID: PMC12609413.
[9] Eledon Pharmaceuticals, Inc. Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine [Internet]. Irvine (CA): Eledon Pharmaceuticals, Inc.; 2026 Mar 16 [cited 2026 May 22]. Available from: https://ir.eledon.com/news-releases/news-release-details/eledon-announces-updated-data-investigator-initiated-islet
[10] Vertex Pharmaceuticals Incorporated. Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings [Internet]. Boston (MA): Vertex Pharmaceuticals Incorporated; 2026 Jan 11 [cited 2026 May 22]. Available from: https://investors.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-1
[11] Sana Biotechnology, Inc. Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression [Internet]. Seattle (WA): Sana Biotechnology, Inc.; 2026 Mar 13 [cited 2026 May 22]. Available from: https://ir.sana.com/news-releases/news-release-details/sana-biotechnology-announces-continued-positive-clinical-results/
